EZH2 is a potential prognostic predictor of glioma
Abstract The enhancer of zeste homologue 2 (EZH2) is a histone H3 lysine 27 methyltransferase that promotes tumorigenesis in a variety of human malignancies by altering the expression of tumour suppressor genes. To evaluate the prognostic value of EZH2 in glioma, we analysed gene expression data and corresponding clinicopathological information from the Chinese Glioma Genome Atlas, the Cancer Genome Atlas and GTEx. Increased expression of EZH2 was significantly associated with clinicopathologic characteristics and overall survival as evaluated by univariate and multivariate Cox regression. Gene Set Enrichment Analysis revealed an association of EZH2 expression with the cell cycle, DNA replication, mismatch repair, p53 signalling and pyrimidine metabolism. We constructed a nomogram for prognosis prediction with EZH2, clinicopathologic variables and significantly correlated genes. EZH2 was demonstrated to be significantly associated with several immune checkpoints and tumour‐infiltrating lymphocytes. Furthermore, the ESTIMATE and Timer Database scores indicated correlation of EZH2 expression with a more immunosuppressive microenvironment for glioblastoma than for low grade glioma. Overall, our study demonstrates that expression of EZH2 is a potential prognostic molecular marker of poor survival in glioma and identifies signalling pathways and immune checkpoints regulated by EHZ2, suggesting a direction for future application of immune therapy in glioma..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
Journal of Cellular and Molecular Medicine - 25(2021), 2, Seite 925-936 |
| Beteiligte Personen: |
Chen, Yi‐nan [VerfasserIn] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine |
|---|
| Umfang: |
12 |
|---|
| doi: |
10.1111/jcmm.16149 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
WLY008018251 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | WLY008018251 | ||
| 003 | DE-627 | ||
| 005 | 20230307173927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230216s2021 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1111/jcmm.16149 |2 doi | |
| 028 | 5 | 2 | |a JCMM_JCMM16149.xml |
| 035 | |a (DE-627)WLY008018251 | ||
| 035 | |a (WILEY)JCMM16149 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 082 | 0 | 4 | |a 610 |q ASE |
| 084 | |a 44.46 |2 bkl | ||
| 100 | 1 | |a Chen, Yi‐nan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a EZH2 is a potential prognostic predictor of glioma |
| 264 | 1 | |c 2021 | |
| 300 | |a 12 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine | ||
| 520 | |a Abstract The enhancer of zeste homologue 2 (EZH2) is a histone H3 lysine 27 methyltransferase that promotes tumorigenesis in a variety of human malignancies by altering the expression of tumour suppressor genes. To evaluate the prognostic value of EZH2 in glioma, we analysed gene expression data and corresponding clinicopathological information from the Chinese Glioma Genome Atlas, the Cancer Genome Atlas and GTEx. Increased expression of EZH2 was significantly associated with clinicopathologic characteristics and overall survival as evaluated by univariate and multivariate Cox regression. Gene Set Enrichment Analysis revealed an association of EZH2 expression with the cell cycle, DNA replication, mismatch repair, p53 signalling and pyrimidine metabolism. We constructed a nomogram for prognosis prediction with EZH2, clinicopathologic variables and significantly correlated genes. EZH2 was demonstrated to be significantly associated with several immune checkpoints and tumour‐infiltrating lymphocytes. Furthermore, the ESTIMATE and Timer Database scores indicated correlation of EZH2 expression with a more immunosuppressive microenvironment for glioblastoma than for low grade glioma. Overall, our study demonstrates that expression of EZH2 is a potential prognostic molecular marker of poor survival in glioma and identifies signalling pathways and immune checkpoints regulated by EHZ2, suggesting a direction for future application of immune therapy in glioma. | ||
| 700 | 1 | |a Hou, Shi‐qiang |4 aut | |
| 700 | 1 | |a Jiang, Rui |4 aut | |
| 700 | 1 | |a Sun, Jun‐long |4 aut | |
| 700 | 1 | |a Cheng, Chuan‐dong |4 aut | |
| 700 | 1 | |a Qian, Zhong‐run |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Cellular and Molecular Medicine |g 25(2021), 2, Seite 925-936 |w (DE-627)WLY007997361 |x 15824934 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2021 |g number:2 |g pages:925-936 |g extent:12 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_WLY | ||
| 936 | b | k | |a 44.46 |q ASE |
| 951 | |a AR | ||
| 952 | |d 25 |j 2021 |e 2 |h 925-936 |g 12 | ||